ArticleACS omega2026
Development and In Vitro Efficacy of Macrophage-Targeted Nanoparticles Encapsulating Vitamin E Derivatives Garcinoic Acid and α‑13'-Carboxychromanol.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Garcinoic acid (GA), a phytomolecule and long-chain metabolite of δ-tocotrienol, and its analogue α-13'-carboxychromanol (α-13'-COOH), derived from α-tocopherol metabolism, are bioactive compounds involved in the regulation of various processes, including immune function and inflammatory responses. Pharmacological properties of these compounds are constrained by the rapid metabolism and the poor target selectivity in distinct tissue or cell types, including macrophages, a main player in the inflammatory response. To overcome these limitations, in this study, the DSPE-PEG-S2P conjugate containing a stabilin-2 receptor-specific S2P peptide was synthesized and utilized for the preparation of nanoparticles (NPs) for macrophage targeting. Also, GA or α-13'-COOH were loaded into nontargeted or macrophage-targeted NPs, and their delivery efficiency was compared against bone marrow-derived macrophages (BMDMs). These NPs exhibited stability for at least 2 days at room and body temperature and provided pH-responsive drug release. Moreover, macrophage-targeted NPs demonstrated a linear dose-dependent increase of cellular levels for both metabolites, whereas nontargeted NPs induced dose-independent accumulation, which emphasizes the targeting ability of the S2P peptide. Additionally, both NPs had no adverse effect on cell morphology and viability. Present findings confirmed the improving effect of S2P-decorated NPs for delivering GA or α-13'-COOH metabolites specifically into these inflammatory cells via targeting macrophages. Cell selectivity and efficacy of this delivery system deserve further preclinical investigation in models of acute and chronic inflammation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.